It's very hard to determine commercial value given the extreme responses. 1 patient is basically cancer free, it saved her life, whilst many others did not benefit. It's would be great for JG to clarify the market for Cantrixil, similarly with Paxalisib comparisons.
It's very hard to determine commercial value given the extreme...
-
- There are more pages in this discussion • 42 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)